Author | Albert J. Chang, MD

Articles

Radium-223: Down to the Bone, and Less Is More

April 17, 2012

Radium-223 is a promising agent that represents a new class of alpha pharmaceuticals that gets down to the site of bony metastases. The limited side-effect profile potentially allows for repeat administration to increase durability of pain control, and for its use in combination with novel biologic and chemotherapeutic agents.